FindTrial
Sign In

Venetoclax combined with azacitidine plus homoharringtonine versus venetoclax combined with azacitidine for relapsed/refractory acute myeloid leukemia: an open-label, multicentre, randomised phase 3 trial

Venetoclax combined with azacitidine plus homoharringtonine versus venetoclax combined with azacitidine for relapsed/refractory acute myeloid leukemia: an open-label, multicentre, randomised phase 3 trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041402
Enrollment
Unknown
Registered
2020-12-25
Start date
2021-01-01
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory acute myeloid leukemia

Interventions

control group:venetoclax combined with azacitidine
Trial group:VAH regimen

Sponsors

Nanfang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with refractory / relapsed acute myeloid leukemia; 2. Patients aged 18-65 years.

Exclusion criteria

Exclusion criteria: 1. Patients with acute promyelocytic leukemia; 2. Patients with life-threatening or treatment complications; 3. Patients with any abnormalities (determined by the investigator) that are not suitable for this study.

Design outcomes

Primary

MeasureTime frame
Overall response rate (including CR/CRi and PR);—

Secondary

MeasureTime frame
Event-free survival;Overall survival;—

Countries

China

Contacts

Public ContactQifa Liu

Nanfang Hospital of Southern Medical University

liuqifa628@163.com+86 13602791429

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026